PRN: Global Immunology Partnering Analysis Report 2010-2016 - Latest Deal Trends, Players and Financials

09/feb/2016 20:11:14 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Immunology Partnering Analysis Report 2010-2016 - Latest Deal Trends, Players and Financials


DUBLIN, Feb. 9, 2016 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Global Immunology Partnering 2010-2016: Deal trends, players and financials" company profile to their offering.

Global Immunology Partnering 2010 to 2016 provides the full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.

The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Global Immunology Partnering 2010 to 2016 includes:

  • Trends in Immunology dealmaking in the biopharma industry since 2010
  • Analysis of Immunology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Immunology deal contract documents
  • Comprehensive access to over 3500 Immunology deal records
  • The leading Immunology deals by value since 2010
  • Most active Immunology dealmakers since 2010

In Global Immunology Partnering 2010 to 2016, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Immunology dealmaking

Chapter 3 - Financial deal terms for Immunology partnering

Chapter 4 - Leading Immunology deals and dealmakers

Chapter 5 - Immunology contract document directory

Chapter 6 - Immunology dealmaking by therapeutic target

For more information visit

Media Contact:

Laura Wood , +353-1-481-1716,



blog comments powered by Disqus è un servizio offerto da Factotum Srl